<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03360448</url>
  </required_header>
  <id_info>
    <org_study_id>RT-01-HF-REF</org_study_id>
    <nct_id>NCT03360448</nct_id>
  </id_info>
  <brief_title>AC6 Gene Transfer in Patients With Reduced Left Ventricular Ejection Fraction Heart Failure</brief_title>
  <acronym>FLOURISH</acronym>
  <official_title>Randomized, Phase 3, Placebo-Controlled Double-Blind, Multicenter Trial of a One Time Intracoronary Administration of Ad5.hAC6 Gene Transfer for Patients With Reduced Left Ventricular Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Renova Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Renova Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and efficacy of an intracoronary injection of adenovirus 5 encoding&#xD;
      human adenylyl cyclase 6 (RT-100) in patients with heart failure with reduced left&#xD;
      ventricular ejection fraction (HFrEF) in a Phase 3 clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, placebo-controlled, double-blinded Phase 3 clinical trial using a&#xD;
      one-time intracoronary injection of Ad5.hAC6 (or placebo) to determine safety and efficacy in&#xD;
      patients with documented HFrEF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Clinical development plans and strategy for RT-100 being re-evaluated&#xD;
  </why_stopped>
  <start_date type="Anticipated">June 2019</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Heart Failure Hospitalizations</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Reduce the event rate of all (first and repeat) heart failure hospitalizations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular (CV) Death</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Reduce the event rate of cardiovascular (CV) death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Death</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Reduce the event rate of death (regardless of cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) Functional Classification</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Improve NYHA functional classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Heart Failure (HF) Events</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Reduce the event rate of all heart failure (HF) events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Echocardiographic Parameters</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Improve echocardiographic parameters of left ventricular systolic and diastolic functions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Improve clinical summary score for heart failure (HF) symptoms and physical limitations as assessed by KCCQ. Scores will be calculated according to the guidance provided by CV Outcomes Inc.</description>
  </other_outcome>
  <other_outcome>
    <measure>Six Minute Walk Distance</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Improve the six-minute walk distance (6MWD) using the standard according to the American Thoracic Society March 2002 Guidelines using a 100 foot hallway or corridor</description>
  </other_outcome>
  <other_outcome>
    <measure>Borg Dyspena Score</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Improve the Borg dyspnea score. The Borg Scale will be used (0-10, 0 = nothing at all, 10 = very, very severe)</description>
  </other_outcome>
  <other_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>Baseline to 3 and 12 months</time_frame>
    <description>Improve N-terminal pro brain natriuretic peptide (NT-proBNP)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad5.hAC6: Intracoronary delivery of adenovirus encoding human adenylyl cyclase type 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: Intracoronary delivery of formulation buffer ( 3% sucrose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ad5.hAC6</intervention_name>
    <description>1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>RT-100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <other_name>3% sucrose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 to 80 years, inclusive, with history of heart failure (HF).&#xD;
&#xD;
          2. Current HF symptoms with NYHA Functional Classification Class II to IV (inclusive) at&#xD;
             Screening (Visit 1).&#xD;
&#xD;
          3. Currently receiving optimally tolerated standard of care HF medical therapy as defined&#xD;
             by the American Heart Association (AHA)/American College of Cardiology (ACC) Heart&#xD;
             Failure guidelines and Focused Update along with an angiotensin converting enzyme&#xD;
             inhibitor (ACEi)/angiotensin II receptor blockers (ARB), diuretics and&#xD;
             sacubitril/valsartan for 4 weeks or longer, without change in drug therapy or dosage&#xD;
             regimen, prior to Visit 1 (and continued same HF therapy through Visit 2).&#xD;
&#xD;
          4. Left Ventricular Ejection Fraction (LVEF) ≥ 10 to ≤ 35% as determined by Screening&#xD;
             echocardiogram (ECHO).&#xD;
&#xD;
          5. NT pro BNP ≥ 400 pg/mL.&#xD;
&#xD;
          6. If subject has had coronary artery bypass surgery, then at least one conduit must be&#xD;
             patent and therefore be amendable for test article.&#xD;
&#xD;
          7. Women of child bearing capacity must have a negative pregnancy test before 2 days of&#xD;
             test article administration and must not be currently breastfeeding or nursing, and&#xD;
             female and male patients must be willing to use birth control for 12 weeks after test&#xD;
             article administration if the female partner is of child bearing capacity. Acceptable&#xD;
             methods of effective birth control include total sexual abstinence; a condom with&#xD;
             spermicide (men) in combination with barrier methods (diaphragm, cervical cap or&#xD;
             cervical sponge); hormonal birth control (oral or injectable contraceptives);&#xD;
             intrauterine devices; or surgical sterilization (vasectomy and testing that shows&#xD;
             there is no sperm in the semen for men and bilateral tubal ligation +/- oophorectomy&#xD;
             for women).&#xD;
&#xD;
          8. Willing to provide informed consent consistent with International Conference on&#xD;
             Harmonisation Good Clinical Practices.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of intravenous (IV) vasodilatory or inotropic therapy within 24 hours prior to&#xD;
             Visit 2.&#xD;
&#xD;
          2. Unstable angina within 3 months of Visit 1.&#xD;
&#xD;
          3. Coronary revascularization planned or predicted within 6 months prior to Visit 1.&#xD;
&#xD;
          4. Subjects who are candidates for revascularization are not considered appropriate for&#xD;
             this trial; therefore, if a subject has Ischemia of viable myocardium &gt; 15% and is a&#xD;
             candidate for revascularization, this subject would not be eligible to participate in&#xD;
             this trial.&#xD;
&#xD;
          5. Myocardial infarction within 6 months prior to Screening (Visit 1). Myocardial&#xD;
             infarction is defined by documented evidence of a rise and/or fall of cardiac&#xD;
             biomarker values (preferably cardiac troponin) with at least one value above the 99th&#xD;
             percentile upper reference limit, and either ischemic symptoms, electrocardiogram&#xD;
             changes, imaging evidence of loss of viable myocardium or new regional wall motion&#xD;
             abnormality, or identification of an intracoronary thrombus by coronary angiography.&#xD;
&#xD;
          6. Thrombocytopenia (&lt; 100,000 platelets/µL) or bleeding diathesis.&#xD;
&#xD;
          7. Stroke or transient ischemic attack within 6 months prior to Screening (Visit 1).&#xD;
&#xD;
          8. Use of sodium-glucose co-transporter 2 inhibitors used to treat type 2 diabetes&#xD;
             mellitus.&#xD;
&#xD;
          9. Cardiac:&#xD;
&#xD;
               1. Biopsy documenting reversible cause of cardiomyopathy within 6 months of Visit 1&#xD;
                  (Screening) if available as part of patient's prior cardiac history.&#xD;
&#xD;
               2. Acute cardiac decompensation.&#xD;
&#xD;
               3. If coronary angiogram within 6 months, with a presence of untreated severe three&#xD;
                  vessel coronary disease or unprotected left main coronary artery disease or&#xD;
                  coronary anatomy unsuitable for study procedure (eg, arterial tortuosity, etc)&#xD;
                  prior to Randomization (Visit 2).&#xD;
&#xD;
               4. Use of IV diuretics within 12 hours of Randomization (Visit 2).&#xD;
&#xD;
               5. Hemodynamically significant untreated valvular heart disease based on the AHA/ACC&#xD;
                  Valvular Heart Disease Guidelines.&#xD;
&#xD;
               6. Current evidence of restrictive, peripartum, viral, infectious, infiltrative, or&#xD;
                  inflammatory cardiomyopathy.&#xD;
&#xD;
               7. Significant pericardial effusion at Screening (Visit 1) or at the time of test&#xD;
                  article administration.&#xD;
&#xD;
               8. Current untreated ventricular arrhythmias.&#xD;
&#xD;
               9. Currently awaiting planned heart transplantation or ventricular assist device.&#xD;
&#xD;
              10. Congenital heart disease (other than small or hemodynamically non significant&#xD;
                  ventricular septal defect or atrial septal defect).&#xD;
&#xD;
              11. Device therapy as noted below:&#xD;
&#xD;
             i. Cardiac resynchronization therapy (CRT), or CRT-D/P, is not allowed within 6 months&#xD;
             of implantation.&#xD;
&#xD;
             ii. Implantable Cardioverter Defibrillator or pacemaker implantation is not allowed if&#xD;
             implanted &lt; 30 days prior to Screening (Visit 1).&#xD;
&#xD;
             iii. CardioMems device is not allowed.&#xD;
&#xD;
             l. Systolic blood pressure ≥ 160 mm Hg or &lt; 90 mm Hg at Visit 1 or 2.&#xD;
&#xD;
             m. Diastolic blood pressure ≥ 95 mm Hg at Visit 1 or 2.&#xD;
&#xD;
         10. 6 Minute Walk Test (6MWT):&#xD;
&#xD;
               1. Inability to perform the 6MWT for reasons unrelated to heart failure (eg,&#xD;
                  physical limitations, peripheral vascular disease).&#xD;
&#xD;
               2. Distance walked in 6MWT (6MWD) &lt; 100 m&#xD;
&#xD;
         11. Pulmonary:&#xD;
&#xD;
               1. Pulmonary disease requiring oxygen therapy;&#xD;
&#xD;
               2. Severe chronic obstructive pulmonary disease; restrictive lung disease.&#xD;
&#xD;
         12. Upper respiratory infection within 4 weeks of Screening (Visit 1).&#xD;
&#xD;
         13. History of organ transplant.&#xD;
&#xD;
         14. Viral syndrome with fever ≥101° Fahrenheit (patient may be reconsidered for enrollment&#xD;
             4 weeks following resolution of viral syndrome).&#xD;
&#xD;
         15. History of human immunodeficiency virus or acquired immunodeficiency syndrome, history&#xD;
             of hepatitis C virus, or immunosuppressed by medicines (corticosteroids, methotrexate,&#xD;
             cyclophosphamide, cyclosporine).&#xD;
&#xD;
         16. Presence of eGFR ≤ 30 mL/min/1.73 m2 using the Cockcroft Gault equation.&#xD;
&#xD;
         17. Patients with life expectancy &lt; 1 year.&#xD;
&#xD;
         18. Documented Child Pugh B or C hepatic disease.&#xD;
&#xD;
         19. Body Mass Index ≥ 40 kg/m2.&#xD;
&#xD;
         20. Participation in any other clinical trial or registry within 30 days prior to&#xD;
             Randomization (Visit 2).&#xD;
&#xD;
         21. Hemoglobin ≤ 10 gm/dL.&#xD;
&#xD;
         22. Prior history of malignancy.&#xD;
&#xD;
         23. Prior history of gene transfer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Hammond HK, Penny WF, Traverse JH, Henry TD, Watkins MW, Yancy CW, Sweis RN, Adler ED, Patel AN, Murray DR, Ross RS, Bhargava V, Maisel A, Barnard DD, Lai NC, Dalton ND, Lee ML, Narayan SM, Blanchard DG, Gao MH. Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure: A Randomized Clinical Trial. JAMA Cardiol. 2016 May 1;1(2):163-71. doi: 10.1001/jamacardio.2016.0008.</citation>
    <PMID>27437887</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>November 13, 2017</study_first_submitted>
  <study_first_submitted_qc>November 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2017</study_first_posted>
  <last_update_submitted>June 5, 2019</last_update_submitted>
  <last_update_submitted_qc>June 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gene Transfer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Blinded study - de-identified participant data to become available after completion of study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

